Skip to content
MARKETS / BALCAO / NORD
BALCAO · SERVICES-MANAGEMENT CONSULTING SERVICES · SMALL CAP

Nordicus Partners Corp. NORD

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$-4.0M
$-4.3M
In brief

What this company does

Nordicus’ current life sciences portfolio consists of two promising preclinical biotechnology companies in Orocidin A/S and Bio-Convert A/S led by the accomplished pharmacologist, Allan Wehnert, who serves as CEO of both companies. In October 2025 Nordicus formed a third subsidiary, NoviThera, also to be led by Allan Wehnert. Orocidin A/S is developing a proprietary first-of-its-kind medical treatment for aggressive periodontitis, with Bio-Convert A/S focused on a treatment against oral leukoplakia (OLK) – an oral potentially malignant disorder – by developing a novel proprietary mucoadhesive oral topical formulation designed to treat and reduce dysplasia levels, potentially offering a curative solution for oral leukoplakia. NoviThera is developing a drug for the treatment of psoriasis, an immune-mediated inflammatory disease that causes keratinocyte hyperproliferation and inflammation.

Written from the business description in Nordicus Partners Corporation's annual report to the U.S. Securities and Exchange Commission, filed 14 July 2026. Every sentence was checked against that document before publication.

Growth
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2024 · Revenue 0.0 · Net income -2.9
2M-2M201020122014201620182020202220242025
Compound annual growth
−47.6%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
Operating margin Net margin
FY2024 · Operating -58387.3% · Net -58345.6%
-20000%-40000%201020122014201620182020202220242025
ROE
FY2025 · ROE -6.4%
-2000%-4000%-6000%201020122014201620182020202220242025

Each USD of equity lost 6 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks -4.3
-2M-4M2025

Total assetsUSD 75.5M
EquityUSD 64.3M
CashUSD 20,878.00
Current ratio0.46×

Equity funds 85% of total assets.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B·0.00.0····0.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0·······
EBITDA $B·······−0.00.0·······
Income tax $B·······0.00.0·······
Net income $B−0.0−0.0−0.0−0.0−0.0−0.00.00.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0···············
EPS, diluted $−0.22−0.32−0.29−1.43·−0.010.230.01−0.01−0.020.000.00−0.02−0.05−0.08−0.15
Dividend / sh $················
Payout %················
ROE %−6.4−9.4−33.0−7626.8−207.9−11.7203.9·····−83.5−90.9−73.0−94.8
Shares out B0.020.020.000.010.010.000.030.020.02·······

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 69 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 26 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Management Consulting Services
Listed onOTC market
Incorporated inDelaware
Fiscal year endsMarch 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image